Is Epclusa the best hepatitis C drug currently available?

Epclusa (generic name: Sofosbuvir/Velpatasvir) is widely considered to be one of the most effective and widely applicable oral antiviral drugs currently used to treat hepatitis C. As a fully oral, pan-genotypic DAA (direct antiviral drug) combination therapy, it is suitable for almost all hepatitis C virus genotypes (types 1~6) and can be used without genotyping testing, greatly simplifying the treatment process. This broad-spectrum adaptability, coupled with a high cure rate, has enabled Jisandai to gain great clinical recognition and promotion.

The cure rate of Jisandai is extremely high. In a number of international III clinical studies, the sustained virological response rate (SVR12, that is, after treatment12 weeks of virus undetectable) reached 95% or more, and some patients even approached 100%. Whether it is initial treatment, re-treatment, or patients with liver cirrhosis, Jisandai has shown stable and powerful efficacy. It has few side effects, common ones include mild fatigue, headache, etc. The vast majority of patients can tolerate it well and do not need to interrupt treatment.

At present, Jisandai has been launched in China and has been included in medical insurance. Patients can purchase it through formal channels in domestic hospitals. After reimbursement by medical insurance, the price is more than 3,000 yuan per box, which significantly reduces the burden of treatment. Foreign generic drugs have more price advantages, especially the Indian and Bangladeshi versions. The price is usually around a few hundred yuan. They are suitable for patients who are not covered by medical insurance or have limited financial conditions. The active ingredients of generic drugs are exactly the same as those of the original drugs, and the curative effects are similar.

In summary, Jisandai is considered to be one of the most ideal options for the treatment of hepatitis C due to its high cure rate, broad spectrum adaptability, convenience in taking, and mild side effects. Whether it is patients with early-stage hepatitis C infection or complex patients with liver fibrosis or cirrhosis, Jisandai can provide a safe and effective treatment path. With the continuous optimization of medical insurance policies and the popularization of generic drugs, its accessibility is further improving, providing a strong guarantee for the complete eradication of hepatitis C.

Reference: https://www.epclusa.com/